Innovation in Drug Delivery & Portfolio Renovation with Sofgen Pharmaceuticals
![](/46/pdcnewsitem/12/03/37/2.png)
The Pharma industry is expected to reach $1.9Tn in revenue by 2027, increasing at a rate of 3-6% per year, according to IQVIA1, with some regions being driven by volume, and others by innovation. Growth in developed economies is projected to be slow, while other regions such as Latin America, Eastern Europe and parts of Asia are expected to have a strong growth. As the pharmaceutical industry continues to evolve, CDMOs will play an increasingly important role in drug development and manufacturing.
Leading pharmaceutical Softgel CDMO, Sofgen Pharmaceuticals, part of Procaps Group, is ideally placed to capitalize on this and other changing demands within the market through its range of Softigel technologies that service different patient and consumer needs and its new Softgel facility in the US.
As Latin America´s largest Softgel CDMO, Sofgen by Procaps Group offers contract manufacturing and development services in Softgel advanced technologies for pharmaceutical companies looking for differentiation, while simultaneously improving efficiency, and gaining access to specialized expertise, and unique technologies for fixed-dose combinations in Softgels, as an example.
Our Softgel facility and Center for Pharmaceutical Excellence located in West Palm Beach, US, specializes in the development and manufacturing of high-end softgel technologies, with expertise in complex oral modalities such as hormonal products and high potency compounds, and other differentiated manufacturing technologies.
Sofgen offers a diverse service portfolio that goes from Research for Advanced Delivery Technologies, End-to-end solutions for Orphan / Fast-track developments, pre-clinical and clinical developments for new Molecular Entities, lab analytical services, all the way to bottling & product inspection services.
Our expansion to the United States provides us with a wider capability to deliver our pharmaceutical products to our strategic partners and ensure the continued quality of their brands which are their most valued assets. The increase in production capacities will provide us with the opportunity to deliver a wider product array as we move even closer to our customers in the North American markets as we implement our ambitious growth plans.
The pharmaceutical industry is moving towards personalized medicine, which involves developing drugs tailored to specific patient needs. CDMOs are also increasingly focused on providing customized drug development and manufacturing services to meet the specific needs of their clients. Sofgen Pharmaceuticals, as an integrated CDMO, iCDMO, is investing in investigating what are these specific needs, so we can integrate our advanced oral technologies and services to tackle in a more direct and specific way those needs.
Through our innovative technologies for oral delivery systems, plus our vast knowledge and expertise of more than 45 years in Softgel development and manufacturing, we offer the flexibility, value, and customization of our partners´ needs, driven by our passion to develop customized products that exceed our customers’ expectations, with a relationship model based on connectivity, trust, and empathy.
Sofgen Pharmaceuticals, your flexible partner for Innovation in Softgel delivery.
[1] IQVIA. Global Use of Medicines 2023 Outlook to 2027. Jan 2023.
![Procaps Group](https://www.cphi-online.com/c244854th_S-comp244854.jpg)
Related News
-
News Novo Nordisk launches 'Power of Wegovy' national campaign
Danish drugmaker Novo Nordisk have launched a new national campaign – The Power of Wegovy – that aims to educate those living with obesity on their blockbuster drug Wegovy throughout the United States. -
News Women in Pharma Anniversary: Celebrating Our Heroines of Pharma
Our Women in Pharma interview series is approaching its 1-year anniversary this month, and to celebrate, we are highlighting the Heroines of Pharma that our very own Women in Pharma admire. -
News Sanofi gains rare disease therapy in acquisition of Inhibrx for US$1.7 billion
Sanofi completed the acquisition of the clinical-stage biotech company Inhibrx in late May 2024 after settling on a US$1.7 billion buyout. The acquisition brings with it a rare disease therapy to bollster Sanofi's pipeline. -
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News Sanofi to collaborate with OpenAI and Formation Bio
Pharmaceutical giant Sanofi have announced a collaboration with Formation Bio and OpenAI to build AI-powered software for accelerated drug development. -
News AstraZeneca to build billion-dollar ADC manufacturing site in Singapore
The British-Swedish drugmaker has announced plans to build a US$1.5 billion facility in Singapore for the manufacturing of antibody–drug conjugates (ADCs) to complement their existing cancer drug portfolio. -
News Women in Pharma: Delivering personal and professional success
In our monthly series focusing on women in the pharmaceutical industry, we interview leading experts in the pharmaceutical supply and value chain to discuss the importance of gender diversity in healthcare, the workplace, and beyond. -
News Eisai begins US FDA rolling submission for Alzheimer’s drug Leqembi
Japanese drugmaker Eisai, in partnership with Biogen, have announced that they have begun submitting data on a rolling basis to the US FDA for a marketing application of a subcutaneous injectable form of Alzheimer’s drug Leqembi.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance